Independent
Tenure on this board
8.4 yrs
2 nominees · 5 ballot items.
Election of two Class I directors; Ratification of Baker Tilly as independent auditors; Approval to increase shares under the 2023 Equity Incentive Plan by 20,000,000; Advisory vote to approve executive compensation (say-on-pay); Approval to allow postponement/adjournment to solicit additional proxies if needed.
Elect two Class I directors (Robert Van Nostrand and Jane Wasman) to the Board for three-year terms expiring in 2029.
Ratify Baker Tilly US, LLP as the company’s independent auditors for the fiscal year ending December 31, 2026.
Approve amendment to increase the number of shares authorized for issuance under the 2023 Equity Plan by 20,000,000 shares.
The proposal asks shareholders to approve a board-approved amendment to the Company’s 2023 Amended and Restated Equity Incentive Plan to add 20,000,000 shares to the plan’s share reserve, increasing total available shares for future equity awards from 7,991 to 20,007,991. Management seeks shareholder approval to ensure sufficient equity is available to continue annual grants, new-hire awards, and a previously board-approved 1,065,000 RSU grant to the CEO that is contingent on shareholder approval; the registrant argues this is standard practice for pre-commercial biotech firms and notes the company’s historical burn rate and competitive need to attract and retain talent. Notable governance protections in the amended plan include administration by an independent compensation committee, no liberal share recycling, no evergreen increases, prohibition on discounted options and repricing without shareholder approval, limits on director grants and limited change-of-control acceleration; the plan’s features are positioned to balance talent incentives with shareholder protections. Approval is required under Nasdaq rules and to preserve favorable tax treatment for incentive stock options. If not approved, the company warns it may be unable to grant equity awards, potentially impairing recruitment and retention and requiring cash-based compensation alternatives; the CEO’s approved RSU grant would be forfeited. The board recommends a FOR vote, citing alignment of employee and shareholder interests and necessity to support long-term success.
Non-binding, advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.
This management proposal seeks an advisory, non-binding endorsement of the executive compensation program as disclosed in the proxy. Management frames compensation as pay-for-performance with a strong equity component to align executives’ interests with shareholders and to attract and retain capable leadership in a competitive biotech labor market; the Company reports outreach and investor engagement following the 2025 say-on-pay and notes limited stockholder concerns. A FOR vote supports the board’s current approach; while advisory, the Board and Compensation Committee intend to consider voting outcomes when making future compensation decisions.
Approve authorizing the meeting chair to postpone or adjourn the Annual Meeting, if necessary, to solicit additional proxies to obtain sufficient votes or establish a quorum.
This proposal asks shareholders to approve the board’s request to allow the chairman to adjourn or postpone the 2026 Annual Meeting to solicit additional proxies if there are insufficient votes or no quorum. It is a routine procedural authorization, providing the board flexibility to reconvene and continue solicitation efforts to effectuate business; approval helps ensure that items requiring shareholder approval can be presented again without needing a special meeting. The board recommends a FOR vote because it preserves orderly conduct of the meeting and the ability to secure shareholder approval for substantive proposals while minimizing disruptions from insufficient voting results.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | STATE STREET CORP | 4.51% | 8,396,356 | $36M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 4.05% | 7,525,929 | $32M |
| 3 | BlackRock, Inc. | 3.38% | 6,289,023 | $27M |
| 4 | BlackRock, Inc. | 2.65% | 4,934,787 | $21M |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 1.78% | 3,313,008 | $14M |
| 6 | MARSHALL WACE, LLP | 0.96% | 1,788,908 | $8M |
| 7 | JONES FINANCIAL COMPANIES LLLP | 0.90% | 1,675,077 | $7M |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 0.79% | 1,462,806 | $6M |
| 9 | NORTHERN TRUST CORP | 0.67% | 1,248,634 | $5M |
| 10 | VANGUARD FIDUCIARY TRUST CO | 0.65% | 1,202,839 | $5M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.